Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Neumora Therapeutics (NMRA): Analyst Targets Average $6.30 After Pipeline Reset

Neumora Therapeutics (NMRA): Analyst Targets Average $6.30 After Pipeline Reset

Key Takeaways

  • The central $6.30 stock price target is the arithmetic mean of six verified, current analyst price targets for Neumora Therapeutics, Inc. (NMRA), a clinical-stage neuroscience biopharmaceutical company.
  • That mean of $6.33 is far above the latest verified price of roughly $0.37, implying an upside of more than 1,500% — a very large move.
  • Individual analyst targets span a wide range, from a low of $3 (Stifel) to a high of $14 (Guggenheim), reflecting deep disagreement about the value of the early-stage pipeline.
  • The targets were sharply reset after Neumora's lead depression drug, navacaprant, failed all three Phase 3 KOASTAL studies, prompting its discontinuation and a 35% workforce reduction.
  • Bullish analysts point to NMRA-511 (Alzheimer's disease agitation), NMRA-898 (schizophrenia), and NMRA-215 (obesity), plus an extended cash runway into the third quarter of 2027.
  • The biggest risks are binary clinical readouts, a micro-cap valuation, limited near-term revenue, and the possibility of further dilution.
  • For more detail on this ticker's developments, explore its Major News, Today's Price Move, Forecast, and Earnings pages.

Analyst Price Targets and Consensus View

The $6.30 central target is a calculated average, not an officially published consensus. It is the arithmetic mean of six verifiable analyst price targets: H.C. Wainwright at $7 (reiterated August 24, 2026), Mizuho at $4 (August 17, 2026), Needham at $5 (August 14, 2026), RBC Capital at $5 (August 14, 2026), Stifel at $3 (May 12, 2026), and Guggenheim at $14 (May 8, 2026). The mean works out to about $6.33, rounded to $6.30, with a low-to-high range of $3 to $14.

Data providers show a broad spread depending on how many analysts they count — from roughly $5.25 to about $6.57 — but the underlying individual targets are the source here. Views diverge sharply. Most firms maintain Buy or Outperform ratings, but Stifel sits at Hold with a $3 target, and J.P. Morgan carries a Sell rating without a published target. Guggenheim's $14 target is a notable outlier, while the rest cluster between $3 and $7.

The reasoning has shifted entirely after the KOASTAL failures. Needham's Ami Fadia cut the firm's target to $5 from $8 while removing navacaprant revenue and costs from the model, and RBC's Brian Abrahams lowered the target to $5 from $7. Bulls frame the pipeline as optionality on Alzheimer's agitation and schizophrenia, while bears argue the remaining assets are too early-stage to justify a meaningful premium. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

Neumora shares closed near $0.37 in late October 2026, giving the company a market capitalization around $69 million. Reaching $6.30 would require a gain of roughly 1,600% — a very large move by any standard, and a reversal of a punishing downtrend that took the stock from a 52-week high of $3.65 in February 2026 to a low near $0.32.

The path to a higher valuation runs almost entirely through clinical execution. With no marketed products, Neumora's value rests on data from NMRA-511 in Alzheimer's disease agitation, NMRA-898 in schizophrenia, and NMRA-215 in obesity. Management extended the cash runway into the third quarter of 2027 through the 35% workforce cut, which generates about $10 million in annualized savings. Until these programs generate positive data, the shares are likely to remain hostage to sentiment and cash concerns.

What Could Support a Move Toward the Target

  • Pipeline optionality: NMRA-511, a V1a receptor antagonist for Alzheimer's agitation, is expected to advance toward a Phase 2b study; positive Phase 1 data for NMRA-898 (an M4 positive allosteric modulator) in schizophrenia could re-rate the stock.
  • Cost discipline: The restructuring extends the cash runway into Q3 2027, reducing near-term dilution risk while the company reaches several clinical milestones.
  • Valuation reset: At a roughly $69 million market cap, even modest clinical progress can produce outsized percentage moves in a micro-cap with several catalysts on the calendar.

What Could Prevent the Target From Being Reached

  • Clinical risk: The KOASTAL-1, -2, and -3 failures show how quickly a lead program can collapse; the remaining pipeline is earlier-stage and unproven.
  • Funding and dilution: A pre-revenue company with a runway into late 2027 may still need to raise capital, which can dilute existing shareholders.
  • Concentration risk: With no diversified revenue base, the investment case hinges on a handful of single-trial readouts that carry binary outcomes.
  • Wide analyst disagreement: The $3-to-$14 spread signals low confidence in any single valuation and reflects genuine uncertainty about what the pipeline is worth.

Technical Levels and Market Structure

The chart shows a persistent long-term downtrend. The 52-week low near $0.32, set in mid-October 2026, is the most important support level; a break below it would signal renewed selling pressure. On the upside, the $0.50 area and the $1.00 psychological level mark early resistance zones, while the prior high of $3.65 sits far above the current price. Given the scale of the required move, technical levels matter less than clinical catalysts in shaping the stock's direction.

Time Horizon and What Investors Should Monitor

Analyst targets typically reflect a roughly 12-month research horizon, though firms do not always state this explicitly and horizons can vary. The most important upcoming items are clinical: Phase 1 data for NMRA-898 in schizophrenia, advancement of NMRA-511 toward a Phase 2b Alzheimer's agitation study, and updates on NMRA-215. Investors should also watch the next quarterly earnings report, expected in November 2026, for updated cash guidance, and any analyst revisions or target changes that follow new clinical data or financing activity.

Using AI Tools in My Research Process

I often turn to Tickeron's AI Daily Buy/Sell Signals when monitoring volatile names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. For a catalyst-driven micro-cap, it helps flag momentum changes more quickly than manual review alone, though it serves only as one input alongside independent analysis of clinical updates and financials.

Final Assessment

The question of whether Neumora Therapeutics can reach $6.30 is, in effect, a question about whether its early-stage pipeline can deliver. The $6.30 figure is the average of six analyst targets spanning $3 to $14, and it sits roughly 1,600% above the current price — a very large move that would require successful clinical readouts, renewed investor confidence, and a materially higher valuation for a pre-revenue company. Bulls see hidden optionality in the Alzheimer's, schizophrenia, and obesity programs; bears see binary risk, a short runway, and little to justify a premium after three Phase 3 failures. With the next major data readouts approaching, the target remains an analyst-derived benchmark rather than a forecast, and the outcome will depend on data that has not yet been reported. From what I see, this remains a high-risk setup best suited for those comfortable with binary outcomes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NMRA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for NMRA turns negative, indicating new downward trend

NMRA saw its Momentum Indicator move below the 0 level on November 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 50 similar instances where the indicator turned negative. In 46 of the 50 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for NMRA turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In 20 of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

NMRA broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NMRA's RSI Oscillator exited the oversold zone, 18 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +55.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where NMRA advanced for three days, in 146 of 167 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

The Aroon Indicator entered an Uptrend today. In 71 of 83 cases where NMRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.124) is normal, around the industry mean (3.596). P/E Ratio (-0.409) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. NMRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NMRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
260 Arsenal Place
Phone
+1 857 760-0900
Employees
96
Web
https://www.neumoratx.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.